Resona Asset Management Co. Ltd. purchased a new position in Amedisys, Inc. (NASDAQ:AMED - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund purchased 5,893 shares of the health services provider's stock, valued at approximately $535,000.
Several other institutional investors and hedge funds also recently made changes to their positions in AMED. Blue Trust Inc. lifted its holdings in Amedisys by 55.1% during the 4th quarter. Blue Trust Inc. now owns 349 shares of the health services provider's stock worth $34,000 after buying an additional 124 shares during the last quarter. HBW Advisory Services LLC acquired a new stake in Amedisys in the fourth quarter worth about $38,000. Versant Capital Management Inc lifted its stake in shares of Amedisys by 68.5% in the 4th quarter. Versant Capital Management Inc now owns 450 shares of the health services provider's stock worth $41,000 after acquiring an additional 183 shares during the period. Vestcor Inc bought a new position in Amedisys during the 4th quarter valued at $73,000. Finally, Venturi Wealth Management LLC boosted its stake in Amedisys by 397.4% during the fourth quarter. Venturi Wealth Management LLC now owns 975 shares of the health services provider's stock valued at $89,000 after buying an additional 779 shares in the last quarter. 94.36% of the stock is currently owned by hedge funds and other institutional investors.
Amedisys Stock Up 0.3 %
NASDAQ AMED traded up $0.29 during trading on Wednesday, reaching $91.87. The company's stock had a trading volume of 9,706 shares, compared to its average volume of 399,470. The company has a current ratio of 1.19, a quick ratio of 1.19 and a debt-to-equity ratio of 0.05. The stock has a market capitalization of $3.01 billion, a PE ratio of 36.42, a PEG ratio of 1.78 and a beta of 0.89. Amedisys, Inc. has a 1-year low of $82.15 and a 1-year high of $98.95. The business has a 50-day moving average price of $92.17 and a 200-day moving average price of $91.98.
Amedisys (NASDAQ:AMED - Get Free Report) last issued its quarterly earnings data on Wednesday, February 26th. The health services provider reported $0.96 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.05 by ($0.09). Amedisys had a return on equity of 12.20% and a net margin of 3.57%. The business had revenue of $598.05 million during the quarter, compared to the consensus estimate of $602.38 million. On average, research analysts forecast that Amedisys, Inc. will post 4.4 earnings per share for the current fiscal year.
Wall Street Analysts Forecast Growth
AMED has been the subject of a number of research reports. Stephens restated an "equal weight" rating and set a $101.00 target price on shares of Amedisys in a report on Tuesday, March 4th. Royal Bank of Canada reaffirmed an "outperform" rating and set a $100.00 target price on shares of Amedisys in a research note on Wednesday. Four investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Hold" and a consensus price target of $100.75.
Read Our Latest Stock Report on Amedisys
Amedisys Company Profile
(
Free Report)
Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.
Featured Stories
Before you consider Amedisys, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amedisys wasn't on the list.
While Amedisys currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
